Captor Therapeutics Sa Is A Biopharmaceutical Company Based In Baselswitzerlandwith Operations In Wroclawpolandthe Company Specializes In Targeted Protein Degradationtpd Focusing On Developing Therapies For Severe Diseasesincluding Malignancies And Autoimmune Disorderscaptor Therapeutics Became The First European Public Company Dedicated Entirely To Tpd Technology Following Its Debut On The Warsaw Stock Exchange In April 2021 The Company Utilizes Its Proprietary Optigradea C Platformwhich Integrates Protein Engineeringstructural Biologyand Crispr Cas9 Genome Editing To Discover And Optimize Drug Candidatescaptor Therapeutics Is Actively Engaged In Five Research And Development Projects Aimed At Addressing High Unmet Medical Needsthrough Strategic Collaborations With Organizations Like Sosei Heptaresthe Company Enhances Its Capabilities And Expands The Range Of Targets For Its Innovative Therapies
